Book contents
- Frontmatter
- Contents
- Preface
- Figures
- Tables
- Abbreviations
- 1 Introduction: global markets and transnational social movements
- 2 Industry structure and movement opportunities
- 3 Drugs = life: framing access to AIDS drugs
- 4 Movement coherence and mobilization
- 5 Advocacy strategies to address costs
- 6 Institutions to stabilize the market
- 7 Lessons for other campaigns
- 8 Conclusions: implications for research and policy
- References
- Index
- References
References
Published online by Cambridge University Press: 05 June 2014
Book contents
- Frontmatter
- Contents
- Preface
- Figures
- Tables
- Abbreviations
- 1 Introduction: global markets and transnational social movements
- 2 Industry structure and movement opportunities
- 3 Drugs = life: framing access to AIDS drugs
- 4 Movement coherence and mobilization
- 5 Advocacy strategies to address costs
- 6 Institutions to stabilize the market
- 7 Lessons for other campaigns
- 8 Conclusions: implications for research and policy
- References
- Index
- References
Summary
A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
- Type
- Chapter
- Information
- AIDS Drugs For AllSocial Movements and Market Transformations, pp. 277 - 311Publisher: Cambridge University PressPrint publication year: 2013
References
, and . 1998. “Why States Act Through Formal International Organizations.” The Journal of Conflict Resolution 42 (1) (February 1): 3–32.CrossRefGoogle Scholar
. 2003. “Glaxo Will Further Cut Prices Of AIDS Drugs to Poor Nations.” The New York Times, April 27, .
. 2004. “How Ideas Spread: Whose Norms Matter? Norm Localization and Institutional Change in Asian Regionalism.” International Organization 58 (1): 239–75.CrossRefGoogle Scholar
, and . 2012. “Novartis Fights India for Cancer Pill Patent.” Wall Street Journal, August 19, .
, , , , , , and . 2012. “Return to Normal Life After AIDS as a Reason for Lost to Follow up in a Community-based Antiretroviral Treatment Program.” Journal of Acquired Immune Deficiency Syndromes (1999) (March 14), .
, and . 2009. “The Politics of International Regime Complexity.” Perspectives on Politics 7: 13–24.CrossRefGoogle Scholar
2003. “Clinton Group Gets Discount for AIDS Drugs.” The New York Times, October 23, .
, and . 2004. “U.N. Agency Drops 2 Drugs for AIDS Care Worldwide.” The New York Times, June 15, .
. 2010. “‘Saving Lives, Buying Time’: Lessons in Good Subsidy Design.” Policy Brief, March 8.
. 2004. The Truth About the Drug Companies: How They Deceive Us and What to Do About It. 1st edn. New York: Random House.Google Scholar
. 2001. “The Secretary-General Address to the African Summit on HIV/AIDS, Tuberculosis and Other Infectious Diseases,” .
, and . 1992. Against the Odds: The Story of AIDS Drug Development, Politics And Profits. 1st edn. New York: HarperCollins.Google Scholar
. 2012. “Now Free Online Classes from Harvard, Stanford.” The Times Of India, August 5, .
. 2004. “How Do Patents And Economic Policies Affect Access To Essential Medicines In Developing Countries?” Health Affairs 23 (3) (May 1): 155–66. .CrossRefGoogle ScholarPubMed
, and . 2001. “Do Patents for Antiretroviral Drugs Constrain Access to AIDS Treatment in Africa?” JAMA: The Journal of the American Medical Association 286 (15) (October 17): 1886–92.CrossRefGoogle ScholarPubMed
, and . 2002. “Defining and Refining International Donor Support for Combating the AIDS Pandemic.” The Lancet 357: 57–61.CrossRefGoogle Scholar
1994. Political Institutions and Military Change: Lessons from Peripheral Wars. Ithaca, NY: Cornell University Press.Google Scholar
, and . 2010. “What Every CEO Needs to Know About Nonmarket Strategy.” MIT Sloan Management Review, .
, , , , , , et al. 2008. “Health Systems and the Right to Health: An Assessment of 194 Countries.” The Lancet 372 (9655) (December 10): 2047–85. .CrossRefGoogle ScholarPubMed
. 2005. “US FDA Approves South African Generic ARV (2),” .
. 2011. “Inside Views: Corporate Self-Interest and Strategic Choices: Gilead Licenses to Medicines Patent Pool,” .
. 2012. “The Pacific Free Trade Deal That’s Anything but Free.” The Guardian, August 26, .
. 2011. “Global Health Fund Finds Some Fraud, Recoups Losses: NPR.” NPR.org, .
, and . 1999. “The Politics, Power, and Pathologies of International Organizations.” International Organization 53 (4): 699–732.CrossRefGoogle Scholar
. 2007. “Interview.” ACT UP Oral History Project. MIX – The New York Lesbian & Gay Experimental Film Festival, .
. 2007. “Institutional Emergence in an Era of Globalization: The Rise of Transnational Private Regulation of Labor and Environmental Conditions.” American Journal of Sociology 113 (2): 297–351.CrossRefGoogle Scholar
2004. “TRIPS and The Global Pharmaceutical Market.” Health Affairs 23 (3) (May 1): 146–54.CrossRefGoogle ScholarPubMed
. 2008. “USPTO Rejects Gilead’s Patents Covering Key HIV Drugs,” .
, and . 2006. The WTO and Access to Essential Medicines. AEI Health Policy Outlook. American Enterprise Institute, .Google Scholar
1982. “Contestable Markets: An Uprising in the Theory of Industry Structure.” American Economic Review 72 (1): 1–15.Google Scholar
1974. “A Theory of Social Interactions.” Journal of Political Economy 82 (6) (November 1): 1063–93.CrossRefGoogle Scholar
. 2004. The Invisible People: How the U.S. Has Slept Through the Global AIDS Pandemic, the Greatest Humanitarian Catastrophe of Our Time. New York: Free Press.Google Scholar
. 2010. “Personal Communication,” November 8.
, , and . 2012. “Evaluating Online Labor Markets for Experimental Research: Amazon.com’s Mechanical Turk.” Political Analysis (March 2), .
. 2012. “Interview,” May 30.
2002. “Pharmaceuticals in U.S. Health Care: Determinants of Quantity and Price.” Journal of Economic Perspectives 16 (4): 45–66.CrossRefGoogle ScholarPubMed
, and . 2009. Managers of Global Change: The Influence of International Environmental Bureaucracies. Cambridge, MA: MIT Press.CrossRefGoogle Scholar
. 2010. Reviving the Global Education Compact: Four Options for Global Education Funding. Center for Global Development, .Google Scholar
. 2005. The Marketing of Rebellion: Insurgents, Media, and International Activism (Cambridge Studies in Contentious Politics). New York: Cambridge University Press, .CrossRefGoogle Scholar
2012. “Developing Symptoms.” Foreign Affairs, May 1, .
. 2012. “Interview,” July 24.
, , , and . 2009. “The Financial Architecture of the Response to the HIV Epidemic: Challenges and Sustainability Issues.” In The Changing HIV/AIDS Landscape, 161–95. Washington DC: World Bank, .Google Scholar
. 2007. “Paul Hunt: UN Special Rapporteur on the Right to Health.” The Lancet 370 (9585) (August 4): 381, .CrossRefGoogle Scholar
. 2011. “Drug Company’s Loss Could Be Africa’s Gain.” The Guardian, January 3, .
. 2012. “Does EU/India Free Trade Agreement Spell the End of Cheap Drugs for Poor Countries?” The Guardian, February 9, .
. 2010. “Beating Malaria ‘Impossible’ Now.” BBC, October 29, sec. Health, .
. 2003. “Agency, Institutions, and the Enduring Pattern of American Civil-military Relations.” Ph.D. thesis, Georgetown University.
. 2011. “HIV Drugs Sharply Cut Risk of Transmission, Study Finds.” The Washington Post, May 12, .
. 1998. Speech of the WHO Director-General, at the World Health Assembly Meeting of the WHO, Geneva, October 13.
. 2011. “Occupy Wall Street Organizers Consider Value of Camps.” The New York Times, November 15, .
, and . 2011. “Occupy Wall Street Protest Reaches a Crossroads.” The New York Times, November 4, .
. 2004. “Trick or Treat?” Foreign Affairs, October 27, .
. 2008. “The Hardest Problem in the World: Leadership in the Climate Regime.” In The Dispensable Hegemon: Explaining Contemporary International Leadership and Cooperation, and , eds., 73–104. London: Routledge.Google Scholar
2009. “Global AIDS Policy in the Age of Obama.” Journal of HIV/AIDS & Social Services 8 (2): 120–6.CrossRefGoogle Scholar
. 2010b. “After Copenhagen: Climate Governance and the Road Ahead.” Council on Foreign Relations, .
. 2012. “World AIDS Day 2012: A Moment for Optimism?” Duck of Minerva, .
. 2012a. “The Duck of Minerva: An AIDS-Free Generation? HIV Is Not A Fad.” The Duck of Minerva, .
. 2012b. “An AIDS-Free Generation? HIV Is Not A Fad – Joshua Busby.” Global Health Governance, .
, and . 2011. “Hearts or Minds? Persuasive Messages on Climate Change.” Paper presented at the 2010 Western Political Science Association Conference, San Francisco, April 1–4.
2003. “Address Before a Joint Session of the Congress on the State of the Union.” The American Presidency Project, .
. 2012. “Extend the Success Against AIDS to Other Devastating Diseases.” The Washington Post, July 23, .
. 2012. “Malaria Programme Gets Kiss of Death from Global Fund.” Nature, November, .
, and . 2009. “The Christian Right: Wrong on AIDS.” TheBody.com, .
, and . 2011. “Escaping Affect: How Motivated Emotion Regulation Creates Insensitivity to Mass Suffering.” Journal of Personality and Social Psychology 100 (1): 1–15.CrossRefGoogle ScholarPubMed
. 2011. “Vetting the Advocacy Agenda: Network Centrality and the Paradox of Weapons Norms.” International Organization 65 (01): 69–102.CrossRefGoogle Scholar
. 1981. “Mortality and Morbidity Weekly Report,” June 5, .
. 2010. AIDS Surveillance – Trends (1985–2010), .
. 2010. “A Conversation with Michel Kazatchkine, Executive Director of the Global Fund to Fight AIDS, Tuberculosis and Malaria,” .
. Undated. “What We’ve Accomplished,” .
. 2008a. “Clinton HIV/AIDS Initiative – Procurement Consortium List (September 2008),” .
. 2008b. “Antiretroviral Price List,” .
. 2010. “CHAI Drug Quality Policy.”
. 2011. “Antiretrovrial (ARV) Ceiling Price List,” .
. 2003. Focus on the Family Applauds Passage of Global AIDS Bill, .
. 2012. “India: Balancing Public and Private Interests in the Intellectual Property Regime”. Intellectual Property Watch, September 17, .
. 2005. Advocacy for Impact: Lessons from Six Successful Campaigns. Center for Nonprofit Strategies, .Google Scholar
1999. “Norms, Institutions, and National Identity in Contemporary Europe.” International Studies Quarterly 43 (1): 84–114.CrossRefGoogle Scholar
2007. “HIV/AIDS Drugs for Sub-Saharan Africa: How Do Brand and Generic Supply Compare?” PloS One 2 (3): 1–6.CrossRefGoogle ScholarPubMed
, and . 2007. “A Theory of Framing and Opinion Formation in Competitive Elite Environments.” Journal of Communication 57 (1): 99–118.Google Scholar
. 2012. “Changing Global Norms Through Reactive Diffusion: The Case of Intellectual Property Protection of AIDS Drugs.” American Sociological Review 77 (5): 831–53.CrossRefGoogle Scholar
. 2012. “Ivory Worship – Pictures, More From National Geographic Magazine,” October, .
, , , , , , et al. 2011. “Prevention of HIV-1 Infection with Early Antiretroviral Therapy.” New England Journal of Medicine 365 (6) (August 11): 493–505.CrossRefGoogle ScholarPubMed
, and . 2007. “Congressional Insiders Poll.” National Journal, .
1986. “The Political Economy of the Pharmaceutical Industry.” Journal of Economic Literature 24 (3): 1178–217.Google ScholarPubMed
. 2012. “Interview,” March 8.
, , and . 2001. “AIDS Epidemic puts Drug Firms in a Vise: Treatment Vs. Profits.” The Wall Street Journal, March 2.
, ed. 2008. The Political Economy of HIV/AIDS in Developing Countries: TRIPS, Public Health Systems and Free Access. Cheltenham: Edward Elgar Publishing.CrossRefGoogle Scholar
, and . 2000. “Understanding the Domestic Impact of International Norms: A Research Agenda.” International Studies Review 2 (1): 65–87.CrossRefGoogle Scholar
. 2012. “Rhino Crisis Round Up: 430 Rhinos Killed in S Africa & More.” Jetpack by WordPress.com, .
. 1999a. Activities for NGO Representatives Thursday March 25, 1999. Geneva, Switzerland, .Google Scholar
. 1999b. “August 1, 1999 Open Letter to Vice President Al Gore, Signed by 307 Public Health Experts and Concerned Persons, Regarding US Trade Pressures on South Africa Efforts to Obtain Access to Essential Medicines,” .
. 1999c. “Sign the Open Letter to the WTO Member States Regarding Access to Medical Technologies,” .
. 1999d. Amsterdam Statement to WTO Member States on Access to Medicine. Amsterdam, Holland, .Google Scholar
. 2002a. “Joint Letter from Consumer Project on Technology, Essential Action, Médecins Sans Frontières, Oxfam International, Health GAP Coalition, and the Third World Network to the World Trade Organization’s TRIPS Council,” .
. 2002b. “Sign-on Letter to U.S. Trade Representative Zoellick Circulated by Health GAP and Médecins Sans Frontières,” .
. 2004. “Generic Medicines and U.S.-initiated Conference on Fixed-Dose Combinations,” .
. 2006. “Sign-on Letter to State and USTR Regarding Pressures on Thailand for Issuing Compulsory License,” .
. 2001. “U.S. Drops Case Over AIDS Drugs in Brazil.” The New York Times, June 25, .
, and . 2005. Pills Profits Protest: Chronicle of the Global AIDS Movement. New York: Outcast Films.Google Scholar
. 2010. “Cipla’s Generic HIV Drug Tenofovir Receives USFDA Approval,” .
1996. “The Uses and Abuses of International Price Comparisons.” In Competitive Strategies in the Pharmaceutical Industry, , ed. Washington DC: AEI Press.Google Scholar
. 2001. “Differential Pricing for Pharmaceuticals: Reconciling Access, R&D and Patents.” The Wharton School, University of Pennsylvania, .
, and . 2003. “Differential Pricing for Pharmaceuticals: Reconciling Access, R&D and Patents.” International Journal of Health Care Finance and Economics 3: 183–205.CrossRefGoogle Scholar
, and . 2010. “Malaria Elimination: Worthy, Challenging, and Just Possible.” The Lancet 376 (9752) (November): 1515–17.CrossRefGoogle ScholarPubMed
, , and . 2003. “Letter from Senators Daschle, McCain and Kennedy to the GAO Requesting a Cost Study of HIV/AIDS Drugs,” .
. 2000. The Mystery of Capital: Why Capitalism Triumphs in the West and Fails Everywhere Else. 1st edn. New York: Basic Books.Google Scholar
. 2008. “Isolated Hegemon: The Creation of the International Criminal Court.” In Cooperating Without America: Theories and Case Studies of Non-hegemonic Regimes, and , eds., 142–72. London: Routledge.Google Scholar
. 2009. “The Discursive Process of Legalization: Charting Islands of Persuasion in the ICC Case.” International Organization 63 (01): 33–65.CrossRefGoogle Scholar
. 2012. “International Organizations and Government Killing: Does Naming and Shaming Save Lives?” International Interactions 38 (5): 597–621.CrossRefGoogle Scholar
. 2004. International Trade Meets Public Health: TRIPS and Access to Medicines. Cambridge, MA: Kennedy School of Government, Harvard University.Google Scholar
, , and . 2006. Case Studies in US Trade Negotiation, Volume 1: Making the Rules. Washington DC: Institute for International Economics.Google Scholar
. 2007. “The Politics of PEPFAR: The President’s Emergency Plan for AIDS Relief.” Ethics and International Affairs 21 (3): 277–92.CrossRefGoogle Scholar
. 2001. “Prevention Urged in AIDS Fight: Natsios Says Fund Should Spend Less on HIV Treatment.” Boston Globe, June 7.
. 2005. “AIDS Drugs Hit Roadblock In Africa,” .
. 2011. Dybul on PEPFAR: “The Sky Was the Limit”. Science Speaks: HIV & TB News. Center for Global Health Policy.Google Scholar
. 2012. “The President’s Emergency Plan for AIDS Relief: How George W. Bush and Aides came to ‘Think Big’ on Battling HIV.” Health Affairs 31 (7) (July 1): 1389–96.CrossRefGoogle Scholar
. 2007. “Interview.” ACT UP Oral History Project. MIX – The New York Lesbian & Gay Experimental Film Festival, .
. 2009. “Global-health Stars Converge on Seattle,” .
. 2011. “UNITAID: Innovative Financing for Health and Development,” .
, and . 2010. Power in Numbers: UNITAID, Innovative Financing, and the Quest for Massive Good. New York: PublicAffairs.Google Scholar
. 1972. “Up and Down with Ecology: The ‘Issue Attention’ Cycle.” The Public Interest 28 (Summer): 38–50.Google Scholar
. 2007. “Four Lessons for Developing Countries from the Trade Negotiations over Access to Medicines.” Liverpool Law Review 28: 11–39.CrossRefGoogle Scholar
. 2001. “The Implications of Framing Effects for Citizen Competence.” Political Behavior 23 (3): 225–56.CrossRefGoogle Scholar
2006. “Clinton Makes Up for Lost Time in Battling AIDS,” .
2009. “Child Mortality Rate Declines Globally.” The New York Times, September 10, sec. World, .
1995. “Different Faces of AIDS are Conjured up by Politicians.” The New York Times, July 8.
2008. “Partisan Gap on Global Warming Grows,” .
. 2009. “Personal Communication,” December 3.
. 2012. “Interview,” September 24.
. 2012. Ranbaxy Hires Consultants as Part of Consent Decree with USFDA, .
. 2012. “Heal Thyself.” The Economist, .
, and . 2006. “Secondary Stakeholder Actions and the Selection of Firm Targets,” .
. 2004. “Interview.” ACT UP Oral History Project. MIX – The New York Lesbian & Gay Experimental Film Festival, .
, and . 2008. “Tripping Over Health: U.S. Policy on Patents and Drug Access in Developing Countries (White House and the World Policy Brief).”Center for Global Development, .Google Scholar
, and . 2006. “Coordinating on Lower Prices: Pharmaceutical Pricing under Political Pressure.” The RAND Journal of Economics 37 (2) (July 1): 324–40.CrossRefGoogle ScholarPubMed
1993. “Framing: Toward Clarification of a Fractured Paradigm.” Journal of Communication 43 (4): 51.CrossRefGoogle Scholar
. 2007. The Invisible Cure: Africa, the West, and the Fight Against AIDS. Vol. I. New York: Farrar, Straus and Giroux.Google Scholar
. 1996. Impure Science: AIDS, Activism, and the Politics of Knowledge. University of California Press.Google ScholarPubMed
. 2001. “GSK Licenses ARVs to South African Generic Manufacturer,” .
. 2012. “A Global Health Mystery: What’s Behind the US Government Position on AMFm? Global Health Policy.” Center for Global Development, .
, and . 2012. “One Year Later: What Happened to Non-Communicable Diseases? Global Health Policy.” Center for Global Development, .
, and . 2012. “Should UNITAID Rethink its Raison d’Être?” Center for Global Development, .
. 2007. “From ‘Marvelous Momentum’ to Health Care for All,” .
, , , , , and . 2007. “How to Promote Global Health.” Foreign Affairs, January 23, .
. 2011. “President’s Emergency Plan for AIDS Relief – Approved and Tentatively Approved Antiretrovirals in Association with the President’s Emergency Plan,” .
2012. “Interview,” September 11.
,, , and . 2010. “Call to Action: Priorities for Malaria Elimination.” The Lancet 376 (9752) (November): 1517–21.CrossRefGoogle ScholarPubMed
, and . 2003. “Rationalism v. Constructivism: A Skeptical View.” In Handbook of International Relations, , , and , eds., 52–72. London, Thousand Oaks, CA: Sage Publications.Google Scholar
, and . 2001. “Saints and Markets: Activists and the Supply of Credence Goods.” Journal of Economics & Management Strategy 10 (1): 149–71.CrossRefGoogle Scholar
. 2012. “Clinton Global Initiative: Obama Outlines Steps to Fight Human Trafficking.” Huffington Post, September 24, .
. 2007. “Architecture Amidst Anarchy: Global Health’s Quest for Governance.” Global Health Governance 1 (1): 1–17.Google Scholar
. 2008. “After the Revolution: Global Health Politics in a Time of Economic Crisis and Threatening Future Trends.” Global Health Governance 2 (2): 1–21.Google Scholar
. 2010. “The Challenges of Global Health Governance,” .
. 2007. “‘$100 Laptop’ to Sell to Public.” BBC, September 24, .
. 2005. “Intellectual Property and Public Health: The WTO’s August 2003 Decision in Perspective.” Richard Newfarmer, ed. World Bank, .
. 2008. “Intellectual Property and Public Health: An Overview of the Debate with a Focus on US Policy, Working Paper Number 146.” Center for Global Development, .
, and . 2008. “Tripping over Health: U.S. Policy on Patents and Drug Access in Developing Countries.” In The White House and the World, ed. 215–40. Washington DC: Center for Global Development, .Google Scholar
, and . 2011. “The UN’s Battle With NCDs.” Foreign Affairs, September 20, .
, and . 1998. “International Norm Dynamics and Political Change.” International Organization 52 (04): 887–917.CrossRefGoogle Scholar
, and . 2008. “Trade, Intellectual Property and Access to Affordable HIV Medicines.” In The HIV Pandemic: Local and Global Implications, , , , and , eds., 660–73. Oxford University Press.Google Scholar
. 2002. The Architecture of Markets: An Economic Sociology of Twenty-First-Century Capitalist Societies. Princeton University Press.Google Scholar
. 2008. “Fields, Power, and Social Skill: A Critical Analysis of the New Institutionalisms.” International Public Management Review 9 (1): 227–53.Google Scholar
. 2008. “Public Production of Anti-Retroviral Medicines in Brazil, 1990–2007.” Development and Change 39 (4): 513–36.CrossRefGoogle Scholar
. 2012. “Millennium Development Goal on Safe Drinking Water Reaches Target Early.” The Guardian, March 6, .
. 2000. “Compulsory Licensing Provisions under the TRIPs Agreement: Balancing Pills and Patents.” American University International Law Review 15 (4): 941–74.Google Scholar
. 2012. How to Survive a Plague, .
. 2007. “Interview.” ACT UP Oral History Project. MIX – The New York Lesbian & Gay Experimental Film Festival, .
. 1999. Consumer Boycotts: Effecting Change Through the Marketplace and Media. London: Routledge.Google Scholar
. 2009. A Heart to Serve: The Passion to Bring Health, Hope, and Healing. Hachette Digital, Inc.Google Scholar
. 2006. “Interview: Peter Piot.” The Age of AIDS, .
. 2008. Diarrheal Disease Advocacy: Findings from a Scan of the Global Funding and Policy Landscape, .
. 2007. “Thailand Takes on Drug Industry, and May Be Winning.” The New York Times, April 10, .
. 2001. “Global Oligopoly, Regional Authority and National Power: Crosscurrents in Pharmaceuticals Today and Tomorrow.” In Consolidation and Competition in the Pharmaceutical Industry, , ed. London: Office of Health Economics.Google Scholar
. 2007. “Public Perceptions of Worldwide Malaria and TB Risks Haven’t Risen,” .
. 2012. “Interview.”
(Government Accountability Office). 2005. “Selection of Antiretroviral Medications Provided Under U.S. Emergency Plan is Limited,” .
. 2006. “Spending Requirement Presents Challenges for Allocating Prevention Funding Under the President’s Emergency Plan for AIDS Relief,” .
. 2007. “The Challenge of Global Health,” .
. 2008. “The Wrong Way to Fight AIDS”, The New York Times, July 29, .
. 2012a. “Money or Die.” Foreign Affairs, March 6, .
. 2012b. The End of AIDS? What Are You Smoking?, .
. 2009a. “The U.S. Global AIDS Response: Norms, Interests and the Duty to Treat.” Cambridge, MA: Department of Political Science, MIT.
. 2009b. “A Global Fund for Education: Achieving Education for All.” The Brookings Institution, .
. 2010. Debunking Delusions: The Inside Story of the Treatment Action Campaign. Jacana Media.Google Scholar
, and . 2008. “When Arguments Prevail Over Power: The CITES Procedure for the Listing of Endangered Species.” Global Environmental Politics 8 (2): 123–48.CrossRefGoogle Scholar
. Undated. “Bioequivalence,” .
. 2006. “Personal Communication,” November 6.
. 2012. “Africa’s Elephants are being Slaughtered in Poaching Frenzy.” The New York Times, September 3, sec. World/Africa, .
. 2012. Gilead Sciences Announces New Collaboration with Indian Partners to Reduce Manufacturing Cost and Improve Availability of Emtricitabine-Based Antiretroviral Therapy in Developing Countries, .
. 2012. Occupy Nation: The Roots, the Spirit, and the Promise of Occupy Wall Street. New York: HarperCollins.Google Scholar
. 2001. “The Mosquito Killer.” The New Yorker, July 2, .
2009. Buying Power: A History of Consumer Activism in America. 1st edn. University of Chicago Press.CrossRefGoogle Scholar
. Undated. “Portfolio and Grant Performance,” .
. 2004. “Guide to the Global Fund’s Policies on Procurement and Supply Management,” .
. 2006. “Guide to the Global Fund’s Policies on Procurement and Supply Management,” .
. 2009. “Guide to the Global Fund’s Policies on Procurement and Supply Management,” .
. 2010a. “About the Global Fund,” .
. 2010b. “Resource Allocation,” .
. 2010c. “Global Fund Quality Assurance Policy for Pharmaceutical Products,” .
. 2011a. “Making a Difference – Global Fund Results Report 2011,” .
. 2011b. “Procurement Support Services Progress Report: June 2009–Dec 2010,” .
. 2004. “Interview.” ACT UP Oral History Project. MIX – The New York Lesbian & Gay Experimental Film Festival, .
. 2011a. “Patent Pool Controversies: Part 2.” IP-Health Listserv, .
. 2011b. “No Sense of Urgency – Pressing the STOP Button on the AIDS Response.” IP-Health Listserv, .
. 2012a. “ONE Pitting Global Fund Against PEPFAR?” IP-Health Listserv, .
. 2012b. “Interview,” May 14.
. 2008. “Who Are the Health Eight (or H8)?”, .
2001. “Public Health, Ethics, and Human Rights: A Tribute to the Late Jonathan Mann.” Journal of Law, Medicine & Ethics 29 (2): 121–30.CrossRefGoogle ScholarPubMed
2009. Moving Politics: Emotion and Act Up’s Fight Against AIDS. University of Chicago Press.CrossRefGoogle Scholar
, , , , and . 2009. “Universal Voluntary HIV Testing with Immediate Antiretroviral Therapy as a Strategy for Elimination of HIV Transmission: A Mathematical Model.” The Lancet 373 (9657): 48–57.CrossRefGoogle ScholarPubMed
. 1985. “Economic Action and Social Structure: The Problem of Embeddedness.” American Journal of Sociology 91 (3) (November 1): 481–510.CrossRefGoogle Scholar
. 2012. Fire in the Blood, .
. 2008. Transnational Networks of Influence in South African AIDS Treatment Activism. Center for Social Science Research, University of Cape Town, .Google Scholar
. 2011. “The Treatment Action Campaign’s Struggle for AIDS Treatment in South Africa: Coalition-building Through Networks.” Journal of Southern African Studies 37 (4): 849–68.CrossRefGoogle Scholar
, and . 2008. “Ain’t That a Shame? Hypocrisy, Punishment, and Weak Actor Influence in International Politics.” Unpublished Paper, Harvard and Tufts Universities and the University of Texas.
. 2009. “Prevention Vs. Treament in HIV: Have We Given Prevention a Chance to Shine?” Karen Grepin’s Global Health Blog, .
. 2012. “Court Grants Stay in Google Books Case.” Computerworld, .
. 2005. “Bush and Big Pharma Team Up to Discredit WHO and Generic Medicines: Drug Companies’ Influence on Health Care Policy Worsens Global AIDS Crisis,” .
. 2010. “Personal Communication,” September 14.
. 2011. Corporate Responsibility Report 2011, .
. 2012. “Tanzania’s Plan to Sell Ivory Stockpile Is ‘Ludicrous’, Say Conservationists.” The Guardian, .
. 2012. “Want to Change Academic Publishing? Just Say No.” The Chronicle of Higher Education, September 23, sec. Commentary, .
. 2001. Speech given at the WTO/WHO Conference on Differential Pricing in Oslo, April 8–10, .
. 2004a. “Delivery of the Generic Triple ARV to Poor Nations is Seriously Threatened by Combined Actions of the US Government, Pharma, WHO, UNICEF, UNAIDS, HHS,” .
. 2004b. “Botswana Report,” .
. 2007. “Roadblocks to Generic Access,” .
. 2009. “How Diverted AIDS Funds Resulted in a Million AIDS Deaths and Threaten a Million More,” .
. 2011. “Personal Communication,” June 23.
. 2012. “Divided Advocacy Networks: Conflict and Competition in Global Climate Change Politics.” Working Paper, University of Maryland.
, and . 2012. “The Emergence of Global Attention to Health Systems Strengthening.” Health Policy and Planning (March 8), .
. 1999a. Provisional Agenda: Compulsory Licensing of Patents and Access to Essential Medicines and Medical Technologies. Geneva, Switzerland, .Google Scholar
. 1999b. Increasing Access to Essential Drugs in a Globalised Economy Working Towards Solutions. Amsterdam, Holland, .Google Scholar
1995. Black Radicals and the Civil Rights Mainstream, 1954–1970. University of Tennessee Press.Google Scholar
, and , eds. 2001. Varieties of Capitalism: The Institutional Foundations of Comparative Advantage. New York: Oxford University Press.CrossRefGoogle Scholar
. 2012. “Interview,” March 12.
. 2003. “Interview.” ACT UP Oral History Project. MIX – The New York Lesbian & Gay Experimental Film Festival, .
2002. “Human Rights Norms and Networks in Authoritarian Chile.” In Restructuring World Politics: Transnational Social Movements, Networks, and Norms, , , and , eds., 47–70. 1st edn. Minneapolis: University of Minnesota Press.Google Scholar
, , , and . 2006. Delegation and Agency in International Organizations. Cambridge University Press.CrossRefGoogle Scholar
. 1999. “Meeting Minutes: HIV/AIDS Forum on Africa.”
. 2001a. “Sign-On Letter,” .
. 2001b. “Regarding the Global AIDS Fund Governance and Structure,” .
. 2003. “Trade, Intellectual Property Rights and Patents,” .
. 2004a. “NGO Letter to the Office of the Global AIDS Initiative: 385 U.S. and International Organizations Call Upon U.S. ‘to Ensure That Programs Use the Most Affordable Medicines Available, and Accept the Current Drug Quality Standards of World Health Organization’s Drug Prequalification Program,’ in a Letter to Randall Tobias, 26 March 2004,” .
. 2004b. “Letter to The Honorable Dr. Manmohan Singh,” .
. 2005. “Medicine Procurement of ARVs and Other Essential Medicines in the U.S. Global AIDS Program,” .
. 2007. “Open Letter from Clinicians and Researchers to Mile White, Abbott CEO,” .
. 2008. “U.S. Civil Society Letter to Members of U.S. Congress on IMF Gold Sales and Scaling up Investments in Health and Education,” .
. 2009. “314 Organizations Sign on to Letter to G7 Finance Ministers on Global Fund Funding Gap,” .
. 2004. “Do Pharmaceutical Firms Price Discriminate Across Rich and Poor Countries? Evidence from Antiretroviral Drug Prices,” .
, and . 2012. “When is the Pen Truly Mighty? Regime Type and the Efficacy of Naming and Shaming in Curbing Human Rights Abuses.” British Journal of Political Science FirstView: 1–22.Google Scholar
, , and . 2002. “HIV-related Stigma and Knowledge in the United States: Prevalence and Trends, 1991–1999.” American Journal of Public Health 92 (3) (March): 371–7.CrossRefGoogle Scholar
. 2006. Unexpected Power: Conflict and Change Among Transnational Activists. Cornell Paperbacks. Ithaca, NY: Cornell University Press, .Google Scholar
. 2009. “South Africa’s Treatment Action Campaign: Combining Law and Social Mobilization to Realize the Right to Health.” Journal of Human Rights Practice 1 (1) (March 1): 14–36.CrossRefGoogle Scholar
. 2003. “U.S. Says Ready to Use Generic Drugs in AIDS Fight,” .
. 2011. “Gilead Kickstarts Patent Pool for AIDS Drugs.” Reuters, July 12, .
. 2006. “The Stern Review on the Economics of Climate Change,” .
, , and . 2007. “The Polls—Trends Public Reactions to Global Health Threats and Infectious Diseases.” Public Opinion Quarterly 71 (4) (December 21): 671–92.CrossRefGoogle Scholar
. 2011. “The Problems with Emissions Trading.” Nature (November 25), .
, , , , , , , , and . 2010. “Maternal Mortality for 181 Countries, 1980–2008: A Systematic Analysis of Progress Towards Millennium Development Goal 5.” The Lancet 375 (9726) (May 8): 1609–23.CrossRefGoogle ScholarPubMed
, , , , , , et al. 2011. “Use of Generic Antiretroviral Agents and Cost Savings in PEPFAR Treatment Programs.” Journal of the American Medical Association 304 (3): 313–20.CrossRefGoogle Scholar
. 2001. “Disputed South African Law Will Not Improve Access to Medicines,” .
. 2002. “International Federation of Pharmaceutical Manufacturers Associations (IFPMA).” .
. 2011. “India to Phase Out HIV Drug as per WHO Guidelines,” .
. 2012. “Interview,” March 14.
. 2001. “Consensus Statement on Antiretroviral Treatment for AIDS in Poor Countries.” Topics in HIV Medicine 9 (2) (June): 14–26.Google Scholar
. 2012. “Ranbaxy Taken to Task by FDA over Manufacturing Woes | InPharm,” .
. 2005. Scaling Up Treatment for the Global AIDS Pandemic: Challenges and Opportunities. Washington DC: The National Academies Press.Google Scholar
Interview with Pharmaceutical Executive who Works on Drug Access Issues. 2012. March 14.
. 2010a. “KENYA: Stavudine to Be Phased Out – Gradually,” .
. 2010b. “HEALTH: Control vs Elimination – the Great Malaria Debate.” IRINnews, .
. 2006. “PEPFAR Policy Hinders Treatment in Generic Terms,” .
. 2011. “Concerns About the Process, Principles of Medicines Patent Pool and the Licence.” PetitionBuzz, .
. 2009. “Malaria Treatment Made Cheaper.” The Financial Times, April 17, .
, and . 2005. “Financing Pharmaceutical Innovation: How Much Should Poor Countries Contribute?” The World Bank Economic Review 19 (1): 45–67.CrossRefGoogle Scholar
2012. “Interview,” June 18.
2007. Agenda Setting, the UN, and NGOs: Gender Violence and Reproductive Rights. Washington DC: Georgetown University Press.Google Scholar
. 2006. “Framing AIDS Mobilization and Human Rights in Post-apartheid South Africa.” Perspectives on Politics 4 (04): 663–70.CrossRefGoogle Scholar
. 2012. “Interview,” March 12–13.
. 2005. “Survey of G7 Nations on HIV Spending in Developing Countries – Chartpack – Kaiser Family Foundation,” .
. 2006. “OGAC’s Abstinence, Faithfulness Requirements for PEPFAR Confusing, Undercutting Other HIV-Prevention Efforts, GAO Report Says.” Daily HIV/AIDS Report, .
. 2011a. “The U.S. President’s Emergency Plan for AIDS Relief (PEPFAR),” .
. 2011b. “Disbursements for Health and All Other ODA, 2002–2009 – Kaiser Slides,” .
. 2011c. “Indian Government Rejects Abbott’s Patent Application For Second-Line ARV,” .
. 2012a. “2012 Survey of Americans on HIV/AIDS – Kaiser Family Foundation,” .
. 2012b. “HIV/AIDS at 30: A Public Opinion Perspective – Kaiser Family Foundation.” Accessed August 3, .
. 2008. PEPFAR Suspends Funding for Three Ranbaxy AIDS Drugs Banned by FDA, .
. 2005. U.S. Free Trade Agreements and the Public Health. Law Firm of Mayer Brown Row & Maw, .Google Scholar
. 2002. “Interview With Paisan Tan-Ud.” Gay Men’s Health Crisis, .
. 2012. “Interview,” December 14.
2001. “The Corporate Ethics Crusade.” Foreign Affairs, September 1, .
2006a. Economic Justice in an Unfair World: Toward a Level Playing Field. Princeton University Press.Google Scholar
2006b. “The New Global Slave Trade.” Foreign Affairs, November 1.
, and . 2001. “Japan, Asian-Pacific Security, and the Case for Analytical Eclecticism.” International Security 26 (3): 153–85.CrossRefGoogle Scholar
, and . 1999. “Explaining Costly International Moral Action: Britain’s Sixty-year Campaign against the Atlantic Slave Trade.” International Organization 53 (4): 631–68.CrossRefGoogle Scholar
, and . 1998. Activists Beyond Borders: Advocacy in International Politics. Ithaca, NY: Cornell University Press.Google Scholar
. 2011. “Malaria Eradication No Vague Aspiration, Says Gates.” Reuters, October 19, .
, , , , , and . 2004. “Letter to President Bush,” .
. 1982. “The Demand for International Regimes.” International Organization 36 (2): 325–55.CrossRefGoogle Scholar
, and . 2010. “The Regime Complex for Climate Change,” .
. 2011. “Strategic Development Trends in the World Pharmaceutical Industry.” Managing Global Transitions 9 (3): 207–23.Google Scholar
. 2003. Mountains Beyond Mountains: Healing the World: The Quest of Dr. Paul Farmer. 1st edn. New York: Random House.Google Scholar
, and . 2004. “Is the ‘3 by 5’ Initiative the Best Approach to Tackling the HIV Pandemic?” PLoS Med 1 (2) (November 30): e37.CrossRefGoogle Scholar
. 2008. “A Social Movement Perspective of Stakeholder Collective Action and Influence.” Business & Society 47 (1) (March 1): 21–49.CrossRefGoogle Scholar
, and . 2010. “The Contentiousness of Markets: Politics, Social Movements, and Institutional Change in Markets.” Annual Review of Sociology 36 (1): 249–67.CrossRefGoogle Scholar
, and . 2007. “Social Movements as Extra-Institutional Entrepreneurs: The Effect of Protests on Stock Price Returns.” Administrative Science Quarterly 52 (3): 413–42.CrossRefGoogle Scholar
. 1999. Norms in International Relations: The Struggle Against Apartheid. Ithaca, NY: Cornell University Press.Google Scholar
. 2008. UNAIDS: The First Ten Years. UNAIDS, .
. 2012. “‘Treatment As Prevention’ Rises As Cry In HIV Fight.” NPR, .
2010. World Rule: Accountability, Legitimacy, and the Design of Global Governance. University of Chicago Press.CrossRefGoogle Scholar
, , and . 2001. “The Rational Design of International Institutions.” International Organization 55 (4): 761–99.CrossRefGoogle Scholar
. 2003. “ACT UP Oral History Project.” A Program of Mix – The New York Lesbian & Gay Experimental Film Festival, .
. 2012. “Happy Birthday, ACT UP, Wherever You Are.” Huffington Post, .
. 2012. “Interview,” May 29.
, and . 2007. “Twisting Tongues and Twisting Arms: The Power of Political Rhetoric.” European Journal of International Relations 13 (1): 35–66.CrossRefGoogle Scholar
2011. “States Cut Back Efforts to Provide Drugs for HIV, AIDS.” The Washington Post, May 23, .
, and . 2001. “Bush Defies Europe over Pollution: US Rejects Kyoto as ‘It Makes No Sense’.” The Daily Telegraph, March 30.
. 2004. “The Important World of Drug Prequalification.” 364 (9448): 1830.CrossRef
2003. “Intellectual Property and the Availability of Pharmaceuticals in Poor Countries.” Innovation Policy and the Economy 3 (January 1): 91–129, .CrossRefGoogle Scholar
, , , , , , et al. 2004. “Effectiveness and Safety of a Generic Fixed-dose Combination of Nevirapine, Stavudine, and Lamivudine in HIV-1-infected Adults in Cameroon: Open-label Multicentre Trial.” The Lancet 364 (9428): 29–34.CrossRefGoogle ScholarPubMed
. 2009. “AIDS and the President – An Inside Account.” Commentary, .
2005. Rethinking The World: Great Power Strategies and International Order. Ithaca, NY: Cornell University Press.Google Scholar
. 2003. “Q&A with Bob Levey: Interview with Paul Zeitz.” The Washington Post, April 15, .
. 2012. “Harvard and M.I.T. Offer Free Online Courses.” The New York Times, May 2, sec. Education, .
2009. Boundaries of Contagion: How Ethnic Politics Have Shaped Government Responses to AIDS. 1st edn. Princeton University Press.CrossRefGoogle Scholar
Lilongwe Times. 2010. “W.H.O. Launches New ART Guidelines,” .
. 2001. “The AIDS-drug Warrior.” Salon, .
. 2008. “What Is Artemisinin?: Scientific American.” Scientific American, .
. 2002. “Malaria Control and the Future of International Public Health.” In Contextual Determinants of Malaria, and , eds., 292–330. Washington DC: Resources for the Future.Google Scholar
, and . 2003. GlaxoSmithKline and AIDS Drug Policy. Stanford Graduate School of Business.Google Scholar
. 1999a. “AIDS Activists Circulate Sign-on Letter on African Trade Bills,” .
. 1999b. “BMS Press Briefing on HIV/Africa Initiative,” .
. 2001a. “Comment on Attaran/Gillespie-White and PhRMA Patent Surveys,” .
. 2001b. “Affidavit of James Packard Love.” CPTech.
. 2003. “Interview (Extended Interview from the Film, Pills Profits Protest, directed by Anne-christine d’Adesky and Ann T. Rossetti).”
. 2007. “Recent Examples of the Use of Compulsory Licenses on Patents.” Knowledge Ecology International, .
. 2009. “Personal Communication,” December 4.
. 2011. “KEI Comments on the ITPC Letter to the Medicines Patent Pool Foundation and UNITAID,” .
, , , , , , , et al. 2011. “Progress Towards Millennium Development Goals 4 and 5 on Maternal and Child Mortality: An Updated Systematic Analysis.” The Lancet 378 (9797) (September 24): 1139–65.CrossRefGoogle ScholarPubMed
, , , , , , and . 2003. “Decrease in Prices of Antiretroviral Drugs for Developing Countries: From Political ‘Philanthropy’ to Regulated Markets?” In Economics of AIDS and Access to HIV/AIDS Care in Developing Countries: Issues and Challenges, , , , , , and , eds., 169–212. Paris: Collection Sciences Sociales et Sida.Google Scholar
. 2006. “The Economics of Movement Success: Business Responses to Civil Rights Mobilization.” American Journal of Sociology 111 (4) (January 1): 963–98.CrossRefGoogle Scholar
. 2004a. “White House Gets Pressure on AIDS Plan: Activists, Drug Firms Duel Over Use of Funds For Generic Combination Drugs in Africa.” The Wall Street Journal, .
. 2004b. “White House Aims To Answer Critics Of Its AIDS Fight,” .
, and . 1998. “Combination Antiretroviral Therapy for HIV Infection.” American Family Physician 57 (11) (June): 2789–98.Google ScholarPubMed
. 2004. “Conference: Provoking Hope: A Brown University HIV/AIDS Symposium: Keynote April 24, 2004,” .
. 2012. “Interview,” February 24.
. 2009. “India Patent Rejections Welcomed by HIV/AIDS Groups,” .
Malaria No More. Undated. Who We Are, .
. 2006. “At World Forum, Support Erodes for Private Management of Water.” The New York Times, March 20, sec. International/Americas, .
1996. “Health and Human Rights.” BMJ: British Medical Journal 312 (7036) (April 13): 924–5.CrossRefGoogle ScholarPubMed
, , , , and . 1994. “Health and Human Rights.” Health and Human Rights 1 (1): 6–23.CrossRefGoogle ScholarPubMed
2001. “Jonathan Mann’s Legacy to the 21st Century: The Human Rights Imperative for Public Health.” The Journal of Law, Medicine & Ethics: a Journal of the American Society of Law, Medicine & Ethics 29 (2): 131–8.CrossRefGoogle ScholarPubMed
. 2011. “First Thoughts on the Petition to the Medicines Patent Pool Foundation,” .
. 2000. “The Theory of Contestable Markets.” Lafayette, IN: Dept. of Economics, Purdue University.
. 2011. Intellectual Property, Human Rights and Development: The Role of NGOs and Social Movements. Cheltenham: Edward Elgar Publishing.CrossRefGoogle Scholar
. 2012. “Malaria Subsidy Pilot Soars, but Some See Turbulence Ahead.” Nature Medicine 18 (5): 634–5.CrossRefGoogle ScholarPubMed
, , and . 1996. Comparative Perspectives on Social Movements: Political Opportunities, Mobilizing Structures, and Cultural Framings. Cambridge University Press.CrossRefGoogle Scholar
, and . 2011. “Cool Dudes: The Denial of Climate Change Among Conservative White Males in the United States.” Global Environmental Change 21: 1163–7.CrossRefGoogle Scholar
. 2007. Case Study of the Campaigns Leading to The President’s Emergency Plan for AIDS Relief. U.S. Coalition for Child Survival, .Google Scholar
. 2006. “The Power of Philanthropy,” .
2001. “Indian Company Offers to Supply AIDS Drugs at Low Cost in Africa – New York Times.” The New York Times, February 6, .
. 2002. “New List of Safe AIDS Drugs, Despite Industry Lobby,” The New York Times, March 20, .
. 2005. “A Path to Cheaper AIDS Drugs for Poor Nations,” The New York Times, January 26, .
. 2010. “Global Fight Against AIDS Reports Failure at Fund-Raising.” The New York Times, October 5, .
. 2011. “Gilead to Share 4 AIDS and Hepatitis Drugs With Patent Pool.” The New York Times, July 12, .
. 2012a. “Global Fund’s Executive Director Steps Down.” The New York Times, January 24, .
. 2012b. “Change Rattles Leading Health-Funding Agency.” The New York Times, November 15, sec. Health, .
1994. “The False Promise of International Institutions.” International Security 19 (3): 5–49.CrossRefGoogle Scholar
Medicines for Malaria Venture. 2012. MMV at a Glance, .
. 2008. Lazarus at America’s Doorstep: Elites and Framing in Federal Appropriations for Global AIDS Relief. Cambridge, MA: Harvard University Press.Google Scholar
. 2007. “Interview.” ACT UP Oral History Project. MIX – The New York Lesbian & Gay Experimental Film Festival, .
. 2012. “Interview,” July 14.
, , , and . 2010. “Why Are Antiretroviral Treatment Patients Lost to Follow-up? A Qualitative Study from South Africa.” Tropical Medicine & International Health 15: 48–54.CrossRefGoogle ScholarPubMed
. 2000. Japan’s Initiative in the Fight Against Infectious and Parasitic Diseases on the Occasion of the Kyushu-Okinawa G8 Summit (“Okinawa ID (Infectious Diseases) Initiative”), .
. 2006. “Tripping up TRIPS Debates IP and Health in Bilateral Agreements.” International Journal of Intellectual Property Management 1 (1–2): 37–53.CrossRefGoogle Scholar
. 1999. “People With Aids Are Dying Because of Lack of Access To Life-Saving Drugs,” .
. 2000a. “MSF Calls On Davos Leaders To Stop People Dying of Market Failure – Business CEOs & Politicians Must Take Action To Restart R&D,” .
. 2000b. MSF Statement on New UNAIDS Proposal and Clinton’s Executive Order on Access to HIV/AIDS Medicines, .
. 2000c. “MSF Calls for Replication and Expansion of Successful Efforts to Reduce AIDS Drug Prices,” .
. 2011. “TRIPS, TRIPS Plus and Doha.” MSF Access Campaign, .
. 2011. “AIDS Drug Patents by Abbot, BMS Rejected.” The Times Of India, January 13, .
. 2010. The Emperor of All Maladies: A Biography of Cancer. Reprint. New York: Simon & Schuster.Google Scholar
1990. “Global Prohibition Regimes: The Evolution of Norms in International Society.” International Organization 44 (04): 479–526.CrossRefGoogle Scholar
. 2011. ADAPs with Waiting Lists (9,066 Individuals in 11 States*, as of September 8, 2011), .
. 2012. ADAPs with Waiting Lists (2,030 Individuals in 9 States*, as of July 12, 2012), .
. 2004. “Anti-AIDS Coalition Scolds U.S. White House’s Refusal to Back Cheap Drugs Irks Group,” .
. 2012. Total GHG Emissions (CO, CH, NO, HFCs, PFCs, SF) in 1990, 2000, 2005 and 2008, .
. 2012. Johnson & Johnson Denies Patent Pool Licences For HIV Medicines For The Poor. IP-Watch, .
. 1989. “AZT’s Inhuman Cost – New York Times.” New York Times, August 27, .
. 2005. “How Not to Roll Back Malaria,” October 16, .
. 2012. “The Duck of Minerva: Open Access and IR Journals.” The Duck of Minerva, .
, and . 2006. “Human Rights: A Potentially Powerful Force for Essential Medicines.” Bulletin of the World Health Organization 84 (5): 410–1.Google Scholar
. 2012. “Interview,” April 3.
. 2006. “The Stern Review on the Economics of Climate Change,” .
. 1990. Institutions, Institutional Change, and Economic Performance: The Political Economy of Institutions and Decisions. Cambridge, New York: Cambridge University Press.CrossRefGoogle Scholar
. 2005. “Market Movements: Nongovernmental Organization Strategies to Influence Global Production and Consumption.” Journal of Industrial Ecology 9 (1–2): 115–28.CrossRefGoogle Scholar
. 2010. “Global Warming: The Frameworks Institute on Why the Deniers Are Winning the Argument,” .
, and . 2006. “Reframing the Issue: The WTO Coalition on Intellectual Property and Public Health, 2001.” In Negotiating Trade: Developing Countries in the WTO and NAFTA, ed. . Cambridge University Press.CrossRefGoogle Scholar
. 2008. “Pharmaceutical Pricing Policies in a Global Market,” .
. 2007. “The Power of Partnerships: The President’s Emergency Plan for AIDS Relief Third Annual Report to Congress,” .
. 2008. “The Power of Partnerships: The U.S. President’s Emergency Plan for AIDS Relief,” .
. 2010. “Saving Lives Through Smart Investments: Latest PEPFAR Results,” .
. 2012. Report on Costs of Treatment in the President’s Emergency Plan for AIDS Relief (PEPFAR), .
, and . 2005. “Public Opinion and the Politics of Obesity in America.” Journal of Health Politics, Policy and Law 30 (5) (October 1): 923–54.CrossRefGoogle ScholarPubMed
. 2007. “ONE Campaign and DATA to Merge, Creating World Class Advocacy Organization to Fight Extreme Poverty,” .
. 1999. “Nobel Lecture” December 10, Oslo, Norway, .
. 2008. “Prevention Failure: The Ballooning Entitlement Burden of U.S. Global AIDS Treatment Spending and What to Do About It – Working Paper 144,” .
.2011. Achieving an AIDS Transition: Preventing Infections to Sustain Treatment. 1st edn. Washington DC: Center for Global Development.Google Scholar
. 2001. Cut the Cost: How World Trade Rules Threaten the Health of Poor People. Oxfam.Google Scholar
.2011. Oxfam Reaction to Global Partnership for Education Donor Commitments Pledged Today, .
. 2010. “Why Is the Death of One Million a Statistic?” .
2001. “Persuasion, Frames and Norm Construction.” European Journal of International Relations 7 (1): 37–61.CrossRefGoogle Scholar
. 2010. “The Spill.” FRONTLINE, .
.2012a. “People Living with AIDS,” .
.2012b. “Race and America’s HIV Epidemic – ENDGAME: AIDS in Black America – FRONTLINE,” FRONTLINE, .
, and . 2001. “Altruism, Politics and Bottom Line Intersect at Indian Generics Firm.” Wall Street Journal, March 12, .
. 2012. “Interview,” May 10.
. 2011. “Personal Communication.”
. 2010. “Personal Communication.”
. 2012. “The American-Western European Values Gap.” Pew Global Attitudes Project, .
. 2011. “New Name, New Start: The Global Partnership for Education.” ONE Campaign, .
, and . 2005. Who Benefits from New Medical Technologies? Estimates of Consumer and Producer Surpluses for HIV/AIDS Drugs. NBER Working Paper. National Bureau of Economic Research, Inc, .
. 2005. Statement for Group of 8 Meeting in July 2005: Health Workforces Must Be Supported to Achieve the Millennium Development Goals, .
. 2001. “EPA Chief Lobbied on Warming Before Bush’s Emissions Switch: Memo Details Whitman’s Plea for Presidential Commitment.” Washington Post, March 27.
. 2009. “Interview,” January 28.
. 2012. No Time to Lose: A Life in Pursuit of Deadly Viruses. 1st edn. New York, London: W. W. Norton & Company.Google Scholar
, , , and . 2010. “Countdown to 2015: Assessment of Official Development Assistance to Maternal, Newborn, and Child Health, 2003–08.”The Lancet 376 (9751) (October 30): 1485–96.CrossRefGoogle Scholar
. 2009. “Time for a ‘Third Wave’ of Malaria Activism to Tackle the Drug Stock-out Crisis.” PLoS Med 6 (11) (November 24): e1000188.
. 2010. “Personal Communication,” July 9.
2005. “Human Rights and Global Health: A Research Program.” Metaphilosophy 36 (1–2): 182–209.CrossRefGoogle Scholar
. 1944. The Great Transformation: The Political and Economic Origins of Our Time. 2nd edn. Boston: Beacon Press.Google Scholar
. 2012. “F.D.A. Approves Once-a-Day Pill for H.I.V.” The New York Times, August 27, sec. Business Day, .
. 2008. “U.S. HIV/AIDS and Family Planning/Reproductive Health Assistance: A Growing Disparity within PEPFAR Focus Countries,” ./
1980. Competitive Strategy: Techniques for Analyzing Industries and Competitors. 1st edn. New York: Free Press.Google Scholar
.2008. “The Five Competitive Forces That Shape Strategy.” Harvard Business Review, January.
. 2012. “World Water Forum Declaration Falls Short on Human Rights, Claim Experts.” The Guardian, .
, and . 2010. “Global Access to Essential Medicines.” In Routledge Handbook of Global Public Health, and , eds., 421–32. Abingdon, NY: Routledge.Google Scholar
. 2004. “The Jekyll and Hyde Story of International Trade: The Supreme Court in PhRMA v. Walsh and the TRIPs Agreement.” University of Richmond Law Review 38 (4): 777–838.Google Scholar
. 2008. Market Rebels: How Activists Make or Break Radical Innovations. Princeton University Press.CrossRefGoogle Scholar
. 2007. “This Is Not Charity,” .
. 1999. A Theory of Justice. Rev. edn. Cambridge, MA: Belknap Press of Harvard University Press.Google Scholar
1987. “Essential Drugs: Economics and Politics in International Health.” Health Policy 8 (1) (August): 39–57.CrossRefGoogle Scholar
, and . 1998. “Dilemmas in Drug Development for Tropical Diseases. Experiences with Praziquantel.” Health Policy (Amsterdam, Netherlands) 44 (1) (April): 1–18.CrossRefGoogle ScholarPubMed
. 2012. Global Fund-led Initiative Slashes Cost of anti-Malaria Medicines in Many African Countries, .
. 2012. “Asking Another Advocate to Write About the World Bank’s Broken Promise on Global Education.” RESULTS, .
. 2012a. “Lawsuit Between Google, Authors in U.S. Suspended Pending Appeal.” Yahoo! News, .
.2012b. “GlaxoSmithKline to Reveal More Drug Secrets.” The New York Times, October 11, .
. 2012. “A Story Exposes How the Chinese Government Is Fueling Elephant Slaughter.” Dot Earth Blog, .
. 2011. No Higher Honor: A Memoir of My Years in Washington. Random House Digital, Inc.Google Scholar
. 2008. “President George W. Bush Receives ‘International Medla of Peace’ That Coincides with PEPFAR Milestone on World AIDS Day”. .
. 2012. “Interview,” January 24.
, , and . 1999. The Power of Human Rights: International Norms and Domestic Change. Cambridge University Press.CrossRefGoogle Scholar
. 2002. Feasible Globalizations. Working Paper. National Bureau of Economic Research, .
. 2010a. “Business Strategy and Access to Medicines in Developing Countries.” Global Health Governance 4 (1): 1–14.Google Scholar
. 2010b. “Business Conflict and Global Politics: The Pharmaceutical Industry and the Global Governance of Intellectual Property.” Review of International Political Economy 20 (1): 121–52.CrossRefGoogle Scholar
. 2001. “Look at Brazil.” The New York Times, .
, and . 2008. “The Global Role of the World Health Organization.” Global Health Governance 2 (2): 1–11.Google Scholar
. 2012. “Interview,” June 26.
. 1964. “From Protest to Politics: The Future of the Civil Rights Movement Commentary Magazine,” .
. 2009. “Increased Number Think Global Warming is ‘Exaggerated’,” .
, , , , , , et al. 2010. “Costs and Financial Feasibility of Malaria Elimination.” The Lancet 376 (9752) (November): 1604–15.CrossRefGoogle ScholarPubMed
. 2010. “Economy Wreaks Havoc on Federal AIDS Drug Program.” The New York Times, June 30, .
. 2010. “Interview,” September 13.
. 2003. “Interview.” ACT UP Oral History Project. MIX – The New York Lesbian & Gay Experimental Film Festival, .
. 1996. “Remarks at Opening Ceremony,” AIDS Conference Vancouver, Canada, .
.2002. “An ACT UP founder ‘acts up’ for Africa’s access to AIDS.” In From ACT UP to the WTO: Urban Protest and Community Building in the Era of Globalization, ed. , 88–102. London, New York: Verso.Google Scholar
.2004. “Interview.” ACT UP Oral History Project. MIX – The New York Lesbian & Gay Experimental Film Festival. .
.2012. “Interview,” July 10.
1993. “Pricing, Profits, and Technological Progress in the Pharmaceutical Industry.” Journal of Economic Perspectives 7 (3): 97–115.CrossRefGoogle Scholar
, and . 2002. “Post-TRIPS Options for Access to Patented Medicines in Developing Nations.” Journal of International Economic Law 5 (4) (December 1): 913–39.CrossRefGoogle Scholar
. Undated. “Overview of the Global Fund to Fight AIDS, Tuberculosis and Malaria,” .
. 2003. “Clinton Program Would Help Poor Nations Get AIDS Drugs,” .
.2011. “Researchers Manipulate Drug’s Chemistry in Bid to Lower Treatment Cost.” The Wall Street Journal, May 13, .
. 2004. “Fighting ‘Frankenfoods’: Industry Opportunity Structures and the Efficacy of the Anti-Biotech Movement in Western Europe.” Social Problems 51 (2) (May 1): 243–68.CrossRefGoogle Scholar
, , and . 2006. “The 10-year Struggle to Provide Antiretroviral Treatment to People with HIV in the Developing World.” The Lancet 368 (9534): 541–6.CrossRefGoogle ScholarPubMed
. Undated. “FAQ” .
, , and . 2003. Surmounting Challenges: Procurement of Antiretroviral Medicines in Low- and Middle-income Countries: The Experience of Médecins Sans Frontières. Geneva: WHO.Google Scholar
. 2005. “An Epidemic Failure.” Rolling Stone, June 2, ://.
2001. “TRIPS and the Access to Medicines Campaign.” Wisconsin International Law Journal 20: 481–522.Google Scholar
, and . 2004. “Using Ideas Strategically: The Contest Between Business and NGO Networks in Intellectual Property Rights.” International Studies Quarterly 48 (1): 143–75.CrossRefGoogle Scholar
. 2006. “A Human Rights Approach to the WHO Model List of Essential Medicines.” Bulletin of the World Health Organization 84 (5): 405–6.CrossRefGoogle ScholarPubMed
2007. “The Political Economy of AIDS Treatment: Intellectual Property and the Transformation of Generic Supply.” International Studies Quarterly 51 (3): 559–81.CrossRefGoogle Scholar
. 2009. “The Politics of Patents and Drugs in Brazil and Mexico: The Industrial Bases of Health Policies.” Comparative Politics 42 (1): 41–58. .CrossRefGoogle Scholar
, , , and . 2012. Intellectual Property, Pharmaceuticals, and Public Health: Access to Drugs in Developing Countries. , , , and , eds. Cheltenham: Edward Elgar Publishing.Google Scholar
. 2006. “HIV/AIDS and the Rest of the Global Health Agenda.” The Lancet 84 (12): 923.Google ScholarPubMed
.2008. “Has Donor Prioritization of HIV/AIDS Displaced Aid for Other Health Issues?” Health Policy and Planning 23 (2) (March 1): 95–100.CrossRefGoogle ScholarPubMed
.2009. “A Social Explanation for the Rise and Fall of Global Health Issues.” Bulletin of the World Health Organization 87 (8) (August 1): 608–13.CrossRefGoogle ScholarPubMed
.2010. “Issue Attention in Global Health: The Case of Newborn Survival.” The Lancet 375 (9730) (June): 2045–9.CrossRefGoogle ScholarPubMed
, and . 2012. “Family Planning: a Political Issue.” The Lancet 380 (9837) (July 14): 181–5.CrossRefGoogle ScholarPubMed
, and . 2007. “Generation of Political Priority for Global Health Initiatives: A Framework and Case Study of Maternal Mortality.” The Lancet 370 (9595): 1370–9.CrossRefGoogle ScholarPubMed
. 1986. “Codes of Conduct for Transnational Corporations: The Case of the WHO/UNICEF Code.” International Organization 40 (4) (October 1): 815–40.CrossRefGoogle Scholar
. 1990. Morality and the Market: Consumer Pressure from Corporate Accountability. 1st edn. London: Routledge.Google Scholar
, and . 2005. “GlaxoSmithKline and Developing Country Access to Essential Medicines (A).” Journal of Business Ethics Education 2 (1): 97–122.CrossRefGoogle Scholar
, and . 2006. Drugs into Bodies: Global AIDS Treatment Activism. Westport, CT: Praeger.Google Scholar
2006. “The Pharmaceutical Revolution: Drug Discovery and Development.” In The Process of New Drug Discovery and Development, and , eds., 547–64. New York: Informa Healthcare.Google Scholar
. 2012. “Occupy Wall Street: A Frenzy That Fizzled.” The New York Times, September 18, .
. 2009. Contention and Corporate Social Responsibility. Cambridge Studies in Contentious Politics. New York: Cambridge University Press.CrossRefGoogle Scholar
, and . 2003. “The Power of Activism: Assessing the Impact of NGOs on Global Business.” California Management Review 45 (3) (April 1): 78–101.CrossRefGoogle Scholar
, , and . 2010. “Are Existing Governance Structures Equipped to Deal with Today’s Global Health Challenges? – Towards Systematic Coherence in Scaling Up.” Global Health Governance 2 (2): 1–25.Google Scholar
. 2008. “Are Millions Becoming HIV Positive Because Of ACT UP Paris?” POZ, .
, and . 2001. “AIDS – Will the Next 20 Years Be Different?” The New England Journal of Medicine 344 (23) (June 7): 1781–2.CrossRefGoogle ScholarPubMed
. 2012. “Worldreader: Taking the E-Book Revolution to Africa.” BusinessWeek: Technology, September 6, .
2002. “How Bayer Makes Decisions to Develop New Drugs.” Interfaces 32 (6) (November 1): 77–90.CrossRefGoogle Scholar
. 2011. “Mission Accomplished, Nonprofits Close.” The New York Times, April 1, sec. Business Day, .
. 2003. “Partnership for Action: An Update on the Expansion of Access to HIV Care and Treatment in Africa by the Companies Involved in the Accelerating Access Initiative Since May 2000.” The Accelerating Access Initiative: Lessons Learned from a Public/Private Collaboration BCIU Round Table United Nations General Assembly High-Level Meeting on HIV/AIDS.
. 2004. “Partnership for Action: The Experience of the Accelerating Access Initiatve, 2000–04, and Lessons Learned.” In Delivering Essential Medicines, and , eds., 116–51. London: Royal Institute of International Affairs.Google Scholar
. 2009. “Interview,” December 3.
. 2013. “Personal Communication,” January 8.
. 2001. “Further Slashes of AIDS Drugs Prices,” .
2012. “Shift in Strategy to Treatment as Prevention for HIV/AIDS.” The Washington Post, July 23, .
. 2005. “Foreign Assistance, International Norms, and NGO Development: Lessons from the Russian Campaign.” International Organization 59: 419–49.CrossRefGoogle Scholar
. 2000. The Boys in the Band. Scoop News, .
. 2002. “TRIPS, Pharmaceutical Patents, and Access to Essential Medicines: a Long Way from Seattle to Doha.” Chicago Journal of International Law 3 (1): 27–46.Google ScholarPubMed
. 2009. The Global Politics of Pharmaceutical Monopoly Power. Diemen, Netherlands: AMB.Google Scholar
. 2010. “Interview,” September 13.
, , , and . 2011. “Driving a Decade of Change: HIV/AIDS, Patents and Access to Medicines for All.” Journal of the International AIDS Society 14 (15): 1–12.Google Scholar
, and . 2008. “Malaria Eradication Back on the Table.” Bulletin of the World Health Organization 86 (2) (February): 82.CrossRefGoogle ScholarPubMed
2005. The New Transnational Activism. Cambridge Studies in Contentious Politics. New York: Cambridge University Press, .CrossRefGoogle Scholar
2001. HIV/AIDS Drugs, Patents and the TRIPS Agreement: Issues and Options. Congressional Research Service, Library of Congress.Google Scholar
. 2012. “Ending Demand Won’t Stop Prostitution.” The New York Times, September 22, .
, and . 2012. Tinderbox: How the West Sparked the AIDS Epidemic and How the World Can Finally Overcome It. 1st edn. Penguin Group US.Google Scholar
. 2004a. “Remarks on The Five-Year Strategy for the President’s Emergency Plan for AIDS Relief,” .
. 2004b. “Hearings Before a Subcommittee of the Committee on Appropriations United States Senate One Hundred Eighth Congress Second Session on H.R. 4818/S. 2812,” .
. 2004c. “Interview on the Jim Lehrer NewsHour,” .
. 2002. “Human Right to Health, National Courts, and Access to HIV/AIDS Treatment: A Case Study from Venezuela,” Chicago Journal of International Law 3: 105–14.Google ScholarPubMed
, and . 2006. Brazil’s AIDS Program: A Costly Success. Health Policy Outlook. American Enterprise Institute.Google Scholar
, , , , , and . 2002. “Drug Development for Neglected Diseases: A Deficient Market and a Public-health Policy Failure.” The Lancet 359 (9324) (June 22): 2188–94.CrossRefGoogle Scholar
. 2002. Veto Players: How Political Institutions Work. New York: Russell Sage Foundation.CrossRefGoogle Scholar
. 2010. Outlook 2010, .
. 2010. “Following Trail of Lost AIDS Patients in Africa.” The New York Times, October 25, .
. 2004. “‘Three Ones’ Key Principles,” .
. 2008. “2008 Report on the Global AIDS Epidemic,” .
. 2010. “Key Facts: Progress in Low- and Middle-Income Countries by Region,” .
. 2011a. “AIDS at 30: Nations at the Crossroads,” .
. 2011b. UNAIDS 2011 World AIDS Day Report. Geneva: UNAIDS, .
. 2012a. Together We Will End AIDS, .
. 2012b. More Than 80 Countries Increase Their Domestic Investments for AIDS by over 50% Between 2006 and 2011, .
, and . 2011. “Using TRIPS Flexibilities to Improve Access to HIV Treatment.” .
. 2007. “UNICEF Procurement of HIV/AIDS-Related Supplies.” .
. 2011. “HIV/AIDS Fact Sheet.” .
. 2001. Declaration of Commitment on HIV/AIDS. United Nations General Assembly Special Assembly on HIV/AIDS, .Google Scholar
. 2012a. “Every Woman Every Child,” .
. 2012b. Millennium Development Goals: 2012 Progress Chart, .
. 2012c. “Unprecedented Global Health Movement Yields Gains for Women’s and Children’s Health.” MarketWatch, .
. 2012d. “UN Commission Sets Out Plan to Make Life-saving Health Supplies More Accessible,” .
. 2012e. “United Nations Millennium Development Goals.” Accessed September 23, .
. 2011. “AIDS Treatment,” .
. 1997. Guide to Methods for Students of Political Science. Ithaca, NY: Cornell University Press.Google Scholar
. 2011. “European Carbon Market Plummets.” European Carbon Market Plummets, .
. 2011a. “Ensuring Quality Medicines: A Decade of Prequalification.” WHO Drug Information 25 (3): 231–9.Google Scholar
. 2011b. “Personal Communication,” July 30.
, , and . 2012. “The Climate Threat We Can Beat.” Foreign Affairs, May 1.
, , and . 2010. “A Lifeline to Treatment: The Role of Indian Generic Manufacturers in Supplying Antiretroviral Medicines to Developing Countries.” Journal of the International AIDS Society 13 (35).CrossRefGoogle ScholarPubMed
, , , , , , , , , and . 2010. “Temporal Trends in Generic and Brand Prices of Antiretroviral Medicines Procured with Donor Funds in Developing Countries.” Journal of Generic Medicines: The Business Journal for the Generic Medicines Sector 7 (2): 159–75.CrossRefGoogle Scholar
, , , , , and . 2009. “Global Strategies to Reduce the Price of Antiretroviral Medicines: Evidence from Transactional Databases.” Bulletin of the World Health Organization 87 (7): 520–8.CrossRefGoogle Scholar
, , , , , , and . 2010. “Intervening in Global Markets to Improve Access to HIV/AIDS Treatment: An Analysis of International Policies and the Dynamics of Global Antiretroviral Medicines Markets.” Globalization and Health 6 (9): 1–19.CrossRefGoogle ScholarPubMed
. 2012. “2012 HIV/AIDS Poll – Washington Post–Kaiser Family Foundation.” The Washington Post, .
. 2004. “Letter to President Bush,” .
. 2007. “Letter to Mark Dybul, U.S. Global AIDS Coordinator,” .
. 2010. “WHO Prequalification Programme,” .
. Undated. “Inspections,” .
. 2002. “Scaling up Antiretroviral Therapy in Resource-limited Settings,” .
. 2003. “Scaling up Antiretroviral Therapy in Resource-limited Settings: Treatment Guidelines for a Public Health Approach,” .
. 2004a. “Removal of Antiretroviral Products from the WHO List of Prequalified Medicines,” .
. 2004b. “Two CIPLA AIDS Medicines Back on WHO’s List of Prequalified Medicines,” .
. 2004c. “Hetero Drugs Ltd. Withdraws Antiretrovirals,” .
. 2004d. “Ranbaxy Withdraws All Its Antiretroviral Medicines from WHO’s List of Prequalified Products,” .
. 2006. “Antiretroviral Therapy for HIV Infection in Adults and Adolescents: Recommendations for a Public Health Approach (2006 Revision),” .
. 2008. “Fact Sheet: Top Ten Causes of Death,” .
. 2009a. “WHO | Towards Universal Access: Scaling up Priority HIV/AIDS Interventions in the Health Sector,” .
. 2009b. “Rapid Advice: Antiretroviral Therapy for HIV Infection in Adults and Adolescents,” .
. 2009c. “Diarrhoeal Disease,” .
. 2010a. “More Than Five Million People Receiving HIV Treatment,” .
. 2010b. “Antiretroviral Therapy for HIV Infection in Adults and Adolescents: Recommendations for a Public Health Approach – 2010 Rev,” .
. 2010c. “The WHO Prequalification Programme and the Medicines Patent Pool: A Primer,” .
. 2010d. Every Woman and Every Child: Global Strategy for Women’s and Children’s Health, .
. 2010e. “WHO | World Malaria Report 2010,” .
. 2011a. “Prequalification Programme,” .
. 2011b. “Guideline on Submission of Documentation for Prequalification of Multisource (generic) Finished Pharmaceutical Products (FPPs) Approved by Stringent Regulatory Authorities (SRAs),” .
. 2011c. “WHO Prequalification of Medicines Programme (PQP) Facts and Figures for 2010,” .
. 2011d. “WHO | The Top 10 Causes of Death,” .
. 2012a. “Essential Medicines Selection: WHO Expert Committees,” .
. 2012b. “WHO List of Prequalified Medicinal Products,” .
. 2012c. “WHO | Maternal Mortality,” .
. 2012d. “WHO | ‘Strategic Use’ of HIV Medicines Could Help End Transmission of Virus,” .
, and . 2002. “Accelerating Access Initiative: Widening Access to Care and Support for People Living with HIV/AIDS. Progress Report,” .
. 1991. “The Global Politics of AIDS: The World Health Organization and the International Regime for AIDS.”Charleston: Department of Government and International Studies, University of South Carolina.Google Scholar
. 2004. “Interview.” ACT UP Oral History Project. MIX – The New York Lesbian & Gay Experimental Film Festival, .
. 2012a. “The Role of Formal and Informal Rules in the Internal Lives of International NGOs.” Paper presented at International Studies Association. San Diego, CA.
. 2012b. Internal Affairs: How the Structure of NGOs Transforms Human Rights. Ithaca, NY: Cornell University Press.CrossRefGoogle Scholar
. 2003. “Instructions for the Procurement of Specialized Medicines for HIV/AIDS Programs,” .
. 2007. “Forest Carbon Partnership Facility.”
. Undated. “Aid for HIV/AIDS Crisis in Africa,” .
. Undated. “TRIPS: Agreement on Trade-Related Aspects of Intellectual Property Rights,” .
. 2001. “Declaration on the TRIPS Agreement and Public Health,” .
. 2003. “University IP Policies and Access to Medicines,” .
. 1981. “Lessons from the Big Eradication Campaigns.” World Health Forum 2 (4): 465–90.Google Scholar
. 1999. A Discussion and Critique of Market Transformation: Challenges and Perspectives. Madison: Energy Center of Wisconsin.Google Scholar
. 2008. “Is Universal Access to Antiretroviral Drugs an Emerging International Norm?” Journal of International Relations and Development 11 (4): 415–40.CrossRefGoogle Scholar
. 2004. Strategic Activism: The Rainforest Action Network. Stanford Graduate School of Business.Google Scholar
. 1996. “Culture, Ideology and Strategic Framing.” In Comparative Perspectives on Social Movements, , , and , eds., 261–74. Cambridge University Press.CrossRefGoogle Scholar
. 1992. The Nature and Origins of Mass Opinion. Cambridge, New York: Cambridge University Press.CrossRefGoogle Scholar
. 2011. “Stavudine to Be Phased Out,” .
. 2002. “World Health Organization Prepares List of ‘Quality’ AIDS Medications,” .